Treatment of Candidiasis of the Lip

Initial Assessment and Disease Severity Classification

The American College of Physicians and the Infectious Diseases Society of America recommend classifying lip candidiasis as mild, moderate, or severe based on disease severity, with mild disease presenting with localized erythema and white patches, and moderate-to-severe disease involving extensive erosions, swelling, or systemic symptoms 1, 2

The Infectious Diseases Society of America recommends topical antifungal therapy as the preferred initial approach for mild lip candidiasis, with options including clotrimazole troches 10 mg dissolved in mouth 5 times daily for 7-14 days, and miconazole mucoadhesive buccal tablet 50 mg applied to mucosal surface once daily for 7-14 days (strong recommendation; high-quality evidence) 1, 2
For moderate to severe disease, the Infectious Diseases Society of America recommends oral fluconazole 100-200 mg daily for 7-14 days as the first-line treatment (strong recommendation; high-quality evidence) 1, 2, 3

The Infectious Diseases Society of America recommends itraconazole solution 200 mg once daily for up to 28 days as an alternative treatment for refractory cases (strong recommendation; moderate-quality evidence) 1, 2
Posaconazole suspension 400 mg twice daily for 3 days, then 400 mg daily for up to 28 days, and voriconazole 200 mg twice daily are also recommended as alternative treatments for refractory cases 1, 2

The Infectious Diseases Society of America recommends against treating based on culture results alone, as Candida species are normal oral flora, and positive cultures without clinical symptoms do not warrant treatment 3
Discontinuing topical corticosteroids immediately is also recommended, as prior or concurrent steroid use is a major predisposing factor that perpetuates infection 1, 2

The Infectious Diseases Society of America recommends a minimum treatment duration of 7-14 days for mild disease, even if symptoms resolve earlier, and clinical response should be evident within several days 1, 2
For recurrent infections, the Infectious Diseases Society of America recommends considering chronic suppressive therapy with fluconazole 100 mg three times weekly, though this is usually unnecessary for immunocompetent patients 1, 2

For HIV-infected or immunocompromised patients, the Infectious Diseases Society of America recommends longer treatment courses (14-21 days minimum) and antiretroviral therapy to reduce recurrence risk 1, 2, 3
Chronic suppressive therapy may be necessary for frequent relapses in these patients 1, 2, 3